Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Ledermann

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2017
Front-line therapy of advanced ovarian cancer: new approachesJ A Ledermann
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancerJ A Ledermann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
PARP inhibitors in ovarian cancerJ A Ledermann
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 18, 2000
Novel chemotherapeutic agents in colorectal cancerM P Napier, J A Ledermann
Current Opinion in Oncology|March 1, 1993
Biology of lung cancerJ A Ledermann, R L Souhami
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Optimal treatment for relapsing ovarian cancerJ A Ledermann, R S Kristeleit
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatmentsJ A Ledermann, S Canevari, T Thigpen
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Optimal first-line treatment in ovarian cancerF A Raja, N Chopra, J A Ledermann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 12, 2018
Latest clinical evidence and further development of PARP inhibitors in ovarian cancerM R Mirza, S Pignata, J A Ledermann
Journal of Human Hypertension|June 1, 1992
Primary malignant retroperitoneal germ cell tumour presenting with accelerated hypertensionL J Restrick, J A Ledermann, B I Hoffbrand
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2017
Front-line therapy of advanced ovarian cancer: new approachesJ A Ledermann
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancerJ A Ledermann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
PARP inhibitors in ovarian cancerJ A Ledermann
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 18, 2000
Novel chemotherapeutic agents in colorectal cancerM P Napier, J A Ledermann
Current Opinion in Oncology|March 1, 1993
Biology of lung cancerJ A Ledermann, R L Souhami
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Optimal treatment for relapsing ovarian cancerJ A Ledermann, R S Kristeleit
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatmentsJ A Ledermann, S Canevari, T Thigpen
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Optimal first-line treatment in ovarian cancerF A Raja, N Chopra, J A Ledermann
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 12, 2018
Latest clinical evidence and further development of PARP inhibitors in ovarian cancerM R Mirza, S Pignata, J A Ledermann
Journal of Human Hypertension|June 1, 1992
Primary malignant retroperitoneal germ cell tumour presenting with accelerated hypertensionL J Restrick, J A Ledermann, B I Hoffbrand
Pageof 7